Lipoprotein-associated phospholipase A2: Review of its role as a marker and a potential participant in coronary endothelial dysfunction

Shahar Lavi; Ronit Lavi; Joseph P. McConnell; Lilach O. Lerman; Amir Lerman

doi:10.1007/BF03256243

Lipoprotein-associated phospholipase A₂: Review of its role as a marker and a potential participant in coronary endothelial dysfunction

Shahar Lavi, Ronit Lavi, Joseph P. McConnell, Lilach O. Lerman, Amir Lerman

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

The role of inflammation in atherosclerosis continues to emerge. Lipoprotein-associated phospholipase A₂ (Lp-PLA₂), a novel plasma biomarker, circulates in the blood bound mainly to low-density lipoprotein (LDL) and promotes vascular inflammation. Several epidemiological studies have shown that circulating levels of Lp-PLA₂ are an independent risk factor for cardiovascular events. Recent studies demonstrate that Lp-PLA₂ is also associated with endothelial dysfunction and early atherosclerosis. This review provides an overview of these studies, suggests plausible mechanisms for the association between endothelial dysfunction and Lp-PLA₂, and highlights future potential therapies.

Original language	English (US)
Pages (from-to)	219-226
Number of pages	8
Journal	Molecular Diagnosis and Therapy
Volume	11
Issue number	4
DOIs	https://doi.org/10.1007/BF03256243
State	Published - 2007

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.1007/BF03256243

Cite this

@article{5e458972e5b64689a780fdc972cebe4d,

title = "Lipoprotein-associated phospholipase A2: Review of its role as a marker and a potential participant in coronary endothelial dysfunction",

abstract = "The role of inflammation in atherosclerosis continues to emerge. Lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel plasma biomarker, circulates in the blood bound mainly to low-density lipoprotein (LDL) and promotes vascular inflammation. Several epidemiological studies have shown that circulating levels of Lp-PLA2 are an independent risk factor for cardiovascular events. Recent studies demonstrate that Lp-PLA2 is also associated with endothelial dysfunction and early atherosclerosis. This review provides an overview of these studies, suggests plausible mechanisms for the association between endothelial dysfunction and Lp-PLA2, and highlights future potential therapies.",

author = "Shahar Lavi and Ronit Lavi and McConnell, {Joseph P.} and Lerman, {Lilach O.} and Amir Lerman",

year = "2007",

doi = "10.1007/BF03256243",

language = "English (US)",

volume = "11",

pages = "219--226",

journal = "Molecular Diagnosis and Therapy",

issn = "1177-1062",

publisher = "Adis International Ltd",

number = "4",

}

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2

T2 - Review of its role as a marker and a potential participant in coronary endothelial dysfunction

AU - Lavi, Shahar

AU - Lavi, Ronit

AU - McConnell, Joseph P.

AU - Lerman, Lilach O.

AU - Lerman, Amir

PY - 2007

Y1 - 2007

N2 - The role of inflammation in atherosclerosis continues to emerge. Lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel plasma biomarker, circulates in the blood bound mainly to low-density lipoprotein (LDL) and promotes vascular inflammation. Several epidemiological studies have shown that circulating levels of Lp-PLA2 are an independent risk factor for cardiovascular events. Recent studies demonstrate that Lp-PLA2 is also associated with endothelial dysfunction and early atherosclerosis. This review provides an overview of these studies, suggests plausible mechanisms for the association between endothelial dysfunction and Lp-PLA2, and highlights future potential therapies.

AB - The role of inflammation in atherosclerosis continues to emerge. Lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel plasma biomarker, circulates in the blood bound mainly to low-density lipoprotein (LDL) and promotes vascular inflammation. Several epidemiological studies have shown that circulating levels of Lp-PLA2 are an independent risk factor for cardiovascular events. Recent studies demonstrate that Lp-PLA2 is also associated with endothelial dysfunction and early atherosclerosis. This review provides an overview of these studies, suggests plausible mechanisms for the association between endothelial dysfunction and Lp-PLA2, and highlights future potential therapies.

UR - http://www.scopus.com/inward/record.url?scp=34548433511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548433511&partnerID=8YFLogxK

U2 - 10.1007/BF03256243

DO - 10.1007/BF03256243

M3 - Review article

C2 - 17705576

AN - SCOPUS:34548433511

SN - 1177-1062

VL - 11

SP - 219

EP - 226

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

IS - 4

ER -

Lipoprotein-associated phospholipase A₂: Review of its role as a marker and a potential participant in coronary endothelial dysfunction

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this